上海医药 SH Pharma (2607 HK) 2025 年一季度业绩：符合预期；医药商业创新业务增速瞩目 1Q25 results: in line; remarkable innovative pharmaceutical service business growth [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$10.74 目标价 HK$13.73 HTI ESG 4.2-4.4-3.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$63.18bn / US$8.15bn 日交易额 (3 个月均值) US$7.17mn 发行股票数目 919.07mn 自由流通股 (%) 74% 1 年股价最高最低值 HK$14.60-HK$10.12 注：现价 HK$10.64 为 2025 年 05 月 02 日收盘价 资料来源： Factset 1mth 3mth 12 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600829 证券简称：人民同泰 编号：临2025-010 哈药集团人民同泰医药股份有限公司 关于召开2024年度暨2025年第一季度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 会议召开时间：2025年5月14日（星期三）14:00-16:30。 ● 会议召开地点："全景路演"网站（http://rs.p5w.net）；微信公众号（名称：全景财经）；全景路演 APP。 ● 会议召开方式：网络远程方式。 ● 投资者可将有关问题于2025年5月7日-2025年5月13日12:00前访问http://ir.p5w.net/zj/，或扫描下方二维 码，进入问题征集专题页面，亦可通过电子邮件形式发送至公司邮箱：renmintongtai@hyrmtt.com.cn， 公司将在说明会上对投资者普遍关注的问题进行回答。 一、说明会类型 哈药集团人民同泰医药股份有限公司（以下简称"公司"）分别于2025年4月12日披露了《2024 ...

研究报告 Research Report 6 May 2025 点评 创新业务拉动医药商业板块持续稳健增长 2025 年一季度，上海医药实现营收 707.6 亿元，同比+0.9%。归母 净利润13.3亿元，同比-13.6%，主要受工业利润贡献下滑影响，部 分受一次性损失（3 月子公司上海信谊联合罚款损失约 1.66 亿元） 和资产处置损失约1000万元（去年同期为资产处置收益1.1亿元） 影响；扣非归母净利润 12.6 亿元，同比-8.1%。分板块看： 医药商业板块（分销+零售）：2025 年一季度实现收入 648.8 亿 元，同比+2.6%。我们认为在医药流通大环境整体复苏较慢的背景 下，上海医药的医药商业展现出较强的业绩韧性，主要由医药商 业创新业务拉动。药品合约销售 CSO 业务收入超 18 亿元，同比 +9.9%；创新药分销业务收入 125 亿元，同比+23.2%，其中进口总 代业务收入 86 亿元，同比+9.0%；器械大健康业务收入 109 亿元， 同比+6.9%。商业板块贡献利润 8.3 亿元，同比基本持平。 医药工业板块：2025 年一季度实现收入 58.9 亿元，同比-15.3% （主要受去年 ...

Core Points - The China Securities Index for Hong Kong Stock Connect Medical Comprehensive Index reported a value of 1467.39 points, showing a monthly increase of 0.37%, a three-month increase of 10.32%, and a year-to-date increase of 11.90% [1] - The index is designed to reflect the overall performance of different industry securities within the Hong Kong Stock Connect, categorized according to the China Securities Industry Classification Standard [1] - The top ten weighted stocks in the index include JD Health (15.7%), Alibaba Health (15.39%), Sinopharm (11.5%), Weigao Group (7.35%), MicroPort Medical (4.9%), Ping An Good Doctor (4.63%), Shanghai Pharmaceuticals (3.7%), MicroPort Scientific-B (3.6%), Xianjian Technology (3.16%), and Jinxin Fertility (3.03%) [1] - The index's holdings are entirely composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Industry Breakdown - The industry composition of the index shows that pharmaceutical commerce accounts for 48.51%, medical services for 23.49%, medical consumables for 23.03%, medical devices for 3.98%, and in vitro diagnostics for 0.98% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with provisions for temporary adjustments in case of special events affecting the index sample [2]

Investment Rating - The report maintains an investment rating of "Outperform the Market" for the pharmaceutical sector [2][5]. Core Views - The pharmaceutical sector has seen a 0.49% increase this week, outperforming the CSI 300 index by 0.93 percentage points, ranking 9th among 31 first-level industries [8][28]. - The report highlights the positive impact of favorable policies on the pharmaceutical sector, suggesting a gradual recovery in industry sentiment. It recommends focusing on high-quality targets in the formulation sector and emphasizes the potential of innovative therapies and domestic drug replacements [5][28]. Summary by Sections Industry Performance - The pharmaceutical sector's performance this week was a 0.49% increase, with sub-sectors such as pharmaceutical commerce rising by 3.12% and medical services by 1.69%. In contrast, biological products and traditional Chinese medicine II saw declines of 0.87% and 1.01%, respectively [8][28]. Key News - Baiyi Shenzhou's BCL-2 inhibitor "Sonrotoclax" has been submitted for market approval, targeting specific types of lymphoma and leukemia [28][29]. - Merck KGaA announced a $3.9 billion acquisition of SpringWorks, enhancing its portfolio in the oncology space [28][30]. Key Announcements - Baili Tianheng received approval for two Phase II clinical trials for its innovative drug BL-B01D1, aimed at treating recurrent or metastatic cervical cancer and advanced endometrial cancer [32][33].

九州通（600998） 2024 年年报及 2025 年一季报点评：三新两 化战略成效显著，"公募+私募"Reits 平台开 启轻资产化运营 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 150,140 | 151,810 | 165,919 | 181,323 | 197,954 | | 同比（%） | 6.92 | 1.11 | 9.29 | 9.28 | 9.17 | | 归母净利润（百万元） | 2,174 | 2,507 | 2,809 | 3,158 | 3,529 | | 同比（%） | 4.27 | 15.33 | 12.03 | 12.42 | 11.75 | | EPS-最新摊薄（元/股） | 0.43 | 0.50 | 0.56 | 0.63 | 0.70 | | P/E（现价&最新摊薄） | 12.15 | 10.54 | 9.41 | 8.37 | 7.49 | 证券研究报告·公司点评 ...

Core Viewpoint - The A-share pharmaceutical and biotechnology sector demonstrated resilience in 2024 despite a complex external environment, with innovative drugs entering a phase of realization and development progress catalyzing growth, unaffected by trade wars, positioning it as a key investment theme for 2025 [1][8]. Overall Performance - A-share pharmaceutical and biotechnology companies reported stable performance, with total revenue in 2024 reaching 2.47 trillion yuan, slightly down from 2.50 trillion yuan in 2023, and a net profit attributable to shareholders of 140.26 billion yuan [2][3]. Revenue Breakdown - The overall sector had 499 companies, with a total revenue of 24,651.04 billion yuan in 2024, reflecting a year-on-year decrease of 1.50%. The first quarter of 2025 saw total revenue of 6,037.04 billion yuan, down 6.14% year-on-year [3]. - Sub-sectors such as chemical pharmaceuticals, pharmaceutical commerce, and medical devices achieved positive revenue growth in 2024, while only the medical services sector showed positive growth in Q1 2025 [4]. Individual Company Performance - Among the companies, 234 reported revenue growth in 2024, with 59 companies exceeding a 20% increase. In terms of net profit, 231 companies saw growth, with 140 exceeding 20% [5]. - Shanghai Pharmaceuticals achieved revenue of 275.25 billion yuan in 2024, up 5.75%, with a net profit of 4.55 billion yuan, a 20.82% increase. The company also reported a significant increase in R&D investment [5]. - Jiuzhoutong reported revenue of 151.81 billion yuan in 2024, a 1.11% increase, driven by stable growth in its pharmaceutical distribution business and rapid growth in emerging sectors [6]. Market Attention - The pharmaceutical and biotechnology sector has garnered significant market attention since April, with many companies receiving institutional research interest, particularly those involved in innovative drugs [7]. - Huadong Medicine's recent annual report and Q1 performance attracted considerable institutional investor interest, focusing on product development and future industry trends [7]. Investment Outlook - Analysts remain optimistic about innovative drugs, overseas expansion, and the clearing of procurement policies, suggesting that the sector is entering a growth phase with potential in insulin, orthopedics, and certain generic drug companies [8]. - The market is expected to see increased activity in mergers and acquisitions as the pharmaceutical market undergoes a phase of concentration [8].

证券之星价投圈财报分析工具显示： 财报体检工具显示： 据证券之星公开数据整理，近期南京医药（600713）发布2025年一季报。根据财报显示，南京医药营收 净利润同比双双增长。截至本报告期末，公司营业总收入142.47亿元，同比上升2.11%，归母净利润 1.77亿元，同比上升11.49%。按单季度数据看，第一季度营业总收入142.47亿元，同比上升2.11%，第 一季度归母净利润1.77亿元，同比上升11.49%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率5.96%，同比减1.06%，净利率1.51%，同比增 7.21%，销售费用、管理费用、财务费用总计5.08亿元，三费占营收比3.57%，同比减3.45%，每股净资 产5.35元，同比增6.28%，每股经营性现金流-2.75元，同比增7.45%，每股收益0.14元，同比增9.76% | 项目 | 2024年一季报 | 2025年一季报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 139.53亿 | 142.47 Z | 2.11% | | 归母净利润(元) | 1.59亿 | 1.77亿 | 11 ...

2025 年 4 月 30 日 公司研究 现金牛属性稳固，短期利润承压不改长期价值 ——大参林（603233.SH）2024 年报及 2025 年一季报点评 要点 事件： 1）公司发布 2024 年报，营业收入 264.97 亿元，同比+8.01%；归母净 利润 9.15 亿元，同比-21.58%；扣非归母净利润 8.85 亿元，同比-22.42%；经 营性净现金流 31.06 亿元，同比-2.13%；EPS（基本）0.81 元。 2）公司发布 2025 年一季报，营业收入 69.56 亿元，同比+3.02%；归母净利润 4.60 亿元，同比+15.45%；扣非归母净利润 4.55 亿元，同比+14.82%；经营性 净现金流 17.68 亿元，同比+44.14%。 点评： 消费力拖累短期业绩，现金牛属性稳固：2024Q1~2025Q1，公司单季度营业收 入分别为 67.52/65.93/63.86/67.66/69.56 亿元，同比+13.54%/+9.07%/ +11.42%/-0.63%/+3.02%；归母净利润 3.98/2.59/2.01/0.57/4.60 亿元，同比 -19.79%/-38.40% ...

Core Insights - The healthcare industry is a complex system involving pharmaceuticals, medical services, and health insurance, facing challenges in supply-demand matching globally [1] - The Chinese healthcare sector is undergoing reforms, including the separation of medical services and pharmaceuticals, and cost control measures [1] Group 1: Overview of the Healthcare Industry - The big health industry encompasses a collection of health-related sectors, including medical products and services, as well as health products and services [3] - The upstream of the big health industry chain consists of product and equipment R&D and manufacturing, while the midstream includes pharmaceutical commerce and health services [5] Group 2: Characteristics of the Healthcare Supply Chain - The supply chain structure exhibits a "dumbbell" pattern, with strong entities at both ends (hospitals and suppliers) and a weaker middle (pharmaceutical distribution companies) [6] - There is a significant mismatch in funding cycles, with pharmaceutical wholesalers averaging 152 days for accounts receivable collection, while medical device settlements can take 180 to 360 days [7] - This structural contradiction exacerbates the financial pressure on midstream distribution companies, highlighting their vulnerability in the supply chain [8] Group 3: Financial Challenges for SMEs - Small and medium-sized enterprises in medical distribution face dual challenges due to mismatched funding cycles, often leading to prolonged periods of cash outlay [9] - Payment cycles for specialized medical equipment can exceed 12 months, further straining the financial resources of these SMEs [9] Group 4: Supply Chain Financial Services - There is an urgent need for supply chain financial services to alleviate the financial difficulties faced by midstream distribution companies [10] - Transitioning from traditional credit assessments to data and asset-based credit evaluations is crucial for resolving issues in medical supply chain finance [11] Group 5: Factoring Industry's Role in Healthcare - The healthcare supply chain presents specific business opportunities for factoring services, categorized into pharmaceutical circulation, medical consumables, and medical equipment [12] - Pharmaceutical circulation factoring can utilize "pool factoring" to manage accounts receivable effectively [13] - Medical consumables have unique characteristics that allow for more precise cash flow management, enabling monthly receivables and payments [15] Group 6: Innovative Financial Products - The "Yishangbao" product developed by a factoring company focuses on providing accounts receivable factoring services to upstream suppliers in the healthcare sector [18] - This product features innovative business models, including pure credit financing and pre-approved credit reserves, enhancing efficiency and reducing costs [19] Group 7: Future Trends in Healthcare Supply Chain Finance - Future development in healthcare supply chain finance should focus on innovative concepts and technological empowerment, shifting from reliance on corporate credit to real trade assets [23] - Leveraging big data to create real-time risk monitoring systems can help address financing challenges for SMEs while strengthening risk management [23]